Welcome to NeurologyLive®‘s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive®‘s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
The FDA was busy in June 2024, making a number of decisions on potential new therapeutic agents including granting approvals, a designation, a clearance, an acceptance of application, a recommendation, and issuing a complete response letter.
As part of our monthly clinician spotlight, NeurologyLive® highlighted multiple sclerosis expert Marisa McGinley, DO, the staff neurologist at Cleveland Clinic’s Mellen Center for MS.
Neal K. Shah, CEO of CareYaya Health Technologies, discussed the groundbreaking potential of AI-powered music therapy in revolutionizing dementia care, offering personalized interventions that can improve quality of life.
The executive director of the Association of Movement Disorder Advanced Practice Providers talked about a recent survey highlighting why patients with movement disorders may withhold critical health information from their providers.
The chief executive officer and the chief scientific officer at CureDuchenne talked about a recent webinar that discussed the broad FDA approval of a gene therapy for Duchenne muscular dystrophy, highlighting patient choice and the ongoing efforts to improve treatments. [WATCH TIME: 9 minutes]
